Zalutumumab, or HuMax-EGFr is a fully human IgG1 antibody directed towards the Epidermal Growth Factor receptor (EGFr). It is a product developed solely by Genmab using their highly advanced, state of art antibody laboratories and technology in Utrect, the Netherlands. As an IgG1 antibody, zalutumumab is a strong therapeutic due to its ability to interact with the body’s immune system, which is a key characteristic in treatment of many types of c...
more
Zalutumumab, or HuMax-EGFr is a fully human IgG1 antibody directed towards the Epidermal Growth Factor receptor (EGFr). It is a product developed solely by Genmab using their highly advanced, state of art antibody laboratories and technology in Utrect, the Netherlands. As an IgG1 antibody, zalutumumab is a strong therapeutic due to its ability to interact with the body’s immune system, which is a key characteristic in treatment of many types of cancer. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), or head and neck cancer. The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodies (mAbs). In addition, murine mAbs were tested with great success in mice, but caused an immune response in humans and were thus determined as ineffective in therapeutics.
Specifically, the antibody is produced using Genmab’s recently developed Unibody technology in which many advantages are gained in...
less
